198 related articles for article (PubMed ID: 15688846)
1. [Amphotericin B: the end of an era].
van der Klooster JM; Zandstra DF
Ned Tijdschr Geneeskd; 2005 Jan; 149(2):107-8; author reply 108. PubMed ID: 15688846
[No Abstract] [Full Text] [Related]
2. [Amphotericin B: the end of an era].
Rommes JH; Spronk PE; Saene HK
Ned Tijdschr Geneeskd; 2005 Jan; 149(2):106; author reply 106-7. PubMed ID: 15688845
[No Abstract] [Full Text] [Related]
3. [Amphotericin B: the end of an era].
Oude Lashof AM; Kullberg BJ
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1665-8. PubMed ID: 15453116
[TBL] [Abstract][Full Text] [Related]
4. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
Bellmann R; Cleary JD; Sterba J
Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
[TBL] [Abstract][Full Text] [Related]
5. Mortality rates in comparative trials of formulations of amphotericin B.
Frothingham R
Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201
[No Abstract] [Full Text] [Related]
6. Treatment of systemic fungus infections.
Watanakunakorn C
Compr Ther; 1982 Feb; 8(2):35-43. PubMed ID: 7067388
[No Abstract] [Full Text] [Related]
7. The treatment of systemic mycoses.
Bennett JE
Ration Drug Ther; 1973 Apr; 7(4):1-4. PubMed ID: 4739799
[No Abstract] [Full Text] [Related]
8. The experience is CLEAR.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
[TBL] [Abstract][Full Text] [Related]
9. Antifungal drugs.
Treat Guidel Med Lett; 2008 Jan; 6(65):1-8. PubMed ID: 18157085
[No Abstract] [Full Text] [Related]
10. Antifungal drugs.
Hay RJ
QJM; 1995 Oct; 88(10):681-4. PubMed ID: 7493164
[No Abstract] [Full Text] [Related]
11. Liposomal amphotericin B found safe and effective.
AIDS Patient Care STDS; 1998 Jan; 12(1):69. PubMed ID: 11361899
[No Abstract] [Full Text] [Related]
12. AmBisome today: expanding the perspectives on liposomal amphotericin B.
Richardson M
Acta Biomed; 2006; 77 Suppl 2():3-4. PubMed ID: 16918058
[No Abstract] [Full Text] [Related]
13. Lipid amphotericin B formulations as comparators in clinical trials.
Powers JH; Albrecht R
Clin Infect Dis; 2004 Jan; 38(2):305-6; author reply 306-7. PubMed ID: 14699471
[No Abstract] [Full Text] [Related]
14. AmBisone: an international workshop. Australia. July 8-9, 2000.
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():iii-v; 1-86. PubMed ID: 11995610
[No Abstract] [Full Text] [Related]
15. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
Garbino J; Markham L; Matulionyte R; Rives V; Lew D
Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
[TBL] [Abstract][Full Text] [Related]
16. [New antifungal agents. New prospects in the management of systemic mycoses].
Grau Cerrato S; Alvarez-Lerma F; Mateu de Antonio J
Farm Hosp; 2003; 27(3):191-8. PubMed ID: 12835822
[No Abstract] [Full Text] [Related]
17. [Treatment of mycoses with antibiotics].
Vanbreuseghem R
Maroc Med; 1971 Mar; 51(544):156-62. PubMed ID: 5562086
[No Abstract] [Full Text] [Related]
18. Antifungal drugs.
Treat Guidel Med Lett; 2005 Feb; 3(30):7-14. PubMed ID: 15671963
[No Abstract] [Full Text] [Related]
19. Amphotericin B deoxycholate: time to retire our old standard?
Gallagher JC
Expert Rev Anti Infect Ther; 2005 Jun; 3(3):313-6. PubMed ID: 15954845
[No Abstract] [Full Text] [Related]
20. Amphotericin B: is a lipid-formulation gold standard feasible?
Spellberg B; Witt MD; Beck CK
Clin Infect Dis; 2004 Jan; 38(2):304-5; author reply 306-7. PubMed ID: 14699470
[No Abstract] [Full Text] [Related]
[Next] [New Search]
